Radiation therapy-induced neuro-Sweet disease in a patient with oral squamous cell carcinoma.

Australas J Dermatol

SA Pathology, Adelaide, South Australia, Australia.

Published: May 2017

Neurological involvement is a rare extracutanenous manifestation of Sweet's syndrome. We present a novel case of radiation therapy-induced neuro-Sweet disease in a patient receiving treatment for an oral squamous cell carcinoma.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.12442DOI Listing

Publication Analysis

Top Keywords

radiation therapy-induced
8
therapy-induced neuro-sweet
8
neuro-sweet disease
8
disease patient
8
oral squamous
8
squamous cell
8
cell carcinoma
8
patient oral
4
carcinoma neurological
4
neurological involvement
4

Similar Publications

Bladder cancer is the 10th most common and 13th most deadly cancer worldwide, with urothelial carcinomas being the most common type. Distinguishing between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) is essential due to significant differences in management and prognosis. MRI may play an important diagnostic role in this setting.

View Article and Find Full Text PDF

Broad repression of DNA repair genes in senescent cells identified by integration of transcriptomic data.

Nucleic Acids Res

December 2024

The David and Inez Myers Laboratory for Cancer Research,  Tel Aviv University, Tel Aviv 6997801, Israel.

Cellular senescence plays a significant role in tissue aging. Senescent cells, which resist apoptosis while remaining metabolically active, generate endogenous DNA-damaging agents, primarily reactive oxygen species. Efficient DNA repair is therefore crucial in these cells, especially when they undergo senescence escape, resuming DNA replication and cellular proliferation.

View Article and Find Full Text PDF

Targeted Radionuclide Therapy Activates Prodrugs for Treating Metastasis.

ACS Cent Sci

December 2024

Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.

Over 90% of cancer patients succumb to metastasis, yet conventional frontline therapy struggles to halt the progression of metastatic tumors. Targeted radionuclide therapy, which delivers radiation precisely to tumor sites, shows promise for treating metastasis. The rational design of a prodrug activation platform using radionuclides would be an ideal approach to synergize chemotherapy with targeted radionuclide therapy, yet it has not been established.

View Article and Find Full Text PDF

Dose-volume predictors of cardiac adverse events after high-dose thoracic radiation therapy for lung cancer: a systematic review and meta-analysis.

BMC Cancer

December 2024

Department of Biomedical Sciences, Namur Research Institute for Life Sciences, (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium.

Background: Lung cancer is a leading cause of cancer mortality and may require high-dose thoracic radiation therapy (RT). However, RT significantly increases the risk of radiation-induced cardiac events, such as pericarditis, cardiomyopathy, and ischemic heart diseases. Despite evidence from clinical trials showing that higher RT doses are associated with poorer survival outcomes due to these cardiac effects, data on dose-volume predictors of such events in lung cancer remain sparse.

View Article and Find Full Text PDF

Cranial radiation therapy (RT) for brain cancers is often associated with the development of radiation-induced cognitive dysfunction (RICD). RICD significantly impacts the quality of life for cancer survivors, highlighting an unmet medical need. Previous human studies revealed a marked reduction in plasma brain-derived neurotrophic factor (BDNF) post-chronic chemotherapy, linking this decline to a substantial cognitive dysfunction among cancer survivors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!